FDA Guide Cuts Animal Testing for New Drugs
Published Date: 3/19/2026
Notice
Summary
The FDA just dropped a draft guide to help drug makers use new, smarter testing methods that can reduce animal testing and better predict human safety. This affects drug developers who want to submit safer, more reliable data for approval. Comments are open until May 18, 2026, so get involved early to shape the final rules and possibly save time and money in drug development.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
FDA Encourages Use of NAMs in Submissions
If you develop drugs, FDA published a draft guidance that gives a validation framework and general recommendations for using new approach methodologies (NAMs) in drug development. The guidance covers using nonclinical NAM data to support regulatory submissions (for example, investigational new drug applications and biologics license applications), encourages early engagement with drug review divisions, and is open for comment through May 18, 2026.
NAMs Apply to OTC Topical Monograph Orders
If you make nonprescription topical (OTC) drugs, the draft guidance says NAMs can be used to support nonclinical data for OTC monograph orders issued under section 505G of the FD&C Act. FDA issued this draft guidance in part to satisfy the requirement under section 505G(r)(2)(B), and it is open for comment through May 18, 2026.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-06478 — Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY
The FDA has officially set the review period for VYLOY, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind VYLOY, giving them a chance to extend their patent protection and potentially boost profits. If anyone thinks the dates are wrong or wants to challenge the company’s review speed, they must act by June 2 or September 30, 2026.
2026-06481 — Determination of Regulatory Review Period for Purposes of Patent Extension; HYMPAVZI
The FDA has set the official review period for HYMPAVZI, a new human biological product, so its patent holder can apply for extra patent time. This affects the company behind HYMPAVZI and anyone interested in patent extensions. If you think the dates are wrong or want to challenge the company’s diligence, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06480 — Determination of Regulatory Review Period for Purposes of Patent Extension; EMRELIS
The FDA has officially set the review period for EMRELIS, a medicine patent, so the patent owner can apply for extra protection time. If anyone thinks the dates are wrong, they have until June 2, 2026, to speak up. Also, people can challenge whether the patent owner was diligent during the review by September 30, 2026. This affects patent holders and could impact how long they keep exclusive rights to their product.
2026-06479 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENFLONSIA
The FDA has set the official review period for ENFLONSIA, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind ENFLONSIA and anyone interested in patent rules. If you think the dates are wrong or want to challenge the company’s review speed, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06477 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENCELTO
The FDA has officially set the review period for ENCELTO, a medicine patent, so the company can apply to extend its patent protection. This affects the drug maker by potentially giving them more time to exclusively sell ENCELTO, which can mean more money. If anyone thinks the dates are wrong or the company wasn’t diligent, they have until June 2 or September 30, 2026, to speak up.
2026-06483 — Determination of Regulatory Review Period for Purposes of Patent Extension; INJECTAFER
The FDA has officially set the review period for INJECTAFER, a drug patent up for extension. This means the company can apply to extend their patent protection, potentially keeping their exclusive rights longer and impacting competition and pricing. If anyone thinks the dates are wrong or the company wasn’t diligent, they can speak up by June 2 or September 30, 2026.
Previous / Next Documents
Previous: 2026-05389 — Agency Information Collection Activities; Submission to the Office of Management and Budget (OMB) for Review and Approval; Comment Request; CHIPS Workforce Solution Participant Data Collection
The Department of Commerce is asking for public feedback on a new data collection for the CHIPS Workforce Solution program, which helps track how semiconductor companies use workforce funding. This affects companies receiving CHIPS funds and aims to make reporting easier while ensuring the government gets useful info. Comments are open until May 18, 2026, so don’t miss your chance to weigh in!
Next: 2026-05391 — 60-Day Notice of Proposed Information Collection: Risk Analysis and Management (RAM) OMB Control Number 1405-0204
The Department of State wants to keep collecting info from contractors and grantees to help manage risks better. They’re asking for public feedback by May 18, 2026, before renewing this paperwork, which takes about 1.5 hours per response. This update won’t cost you money but helps keep things safe and smooth for everyone involved.
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in